Trials / Terminated
TerminatedNCT01185223
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Multicenter, Randomized Study Comparing Oral Valganciclovir Versus Intravenous Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 212 (estimated)
- Sponsor
- Pierrel Research Europe GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the efficacy and safety of oral valganciclovir versus intravenous ganciclovir in patients following allogenic stem cell transplantation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Valganciclovir | Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL |
| DRUG | Ganciclovir | 2x5mg/kg/d intravenous ganciclovir |
Timeline
- Start date
- 2010-09-01
- Primary completion
- 2012-12-01
- First posted
- 2010-08-19
- Last updated
- 2012-12-10
Locations
17 sites across 3 countries: Austria, Germany, Spain
Source: ClinicalTrials.gov record NCT01185223. Inclusion in this directory is not an endorsement.